Factor VII is the most prevalent of the rare deficiencies. The North American Rare Bleeding Disorders Registry (NARBDR) has documented that FVII deficient patients represent 46% of reported rare bleeding disorder patients (excluding FXI deficiency). 35% of FVII deficient patients have documented FVII levels of <20% activity level.
Although specific replacement products have been licensed for this disorder in much of the rest of the developed world, no replacement product is currently licensed to treat factor VII deficiency in the US. Recombinant factor VIIa is licensed to treat patients with inhibitors to factor VIII and IX. Multiple reports exist in the literature regarding the use of rFVIIa for treatment of factor VII deficiency.
Click a link below for information about the specific rare factor deficiencies.